China Biologic Products inked an agreement with the Institute of Blood Transfusion (IBT) to strengthen its R&D and manufacturing capabilities. Under the terms of the agreement, China Biologic has priority purchase rights to commercialize any new technologies or products that result from the collaboration.
The arrangement entitles China Biologic to utilize IBT's technologies including its recombinant protein therapeutic, mAb, and diagnostic methodologies. The company will leverage these technologies to increase the range of plasma-derivative products that it can manufacture as well as to enhance safe and efficient plasma collection.
China Biologic will provide partial funding, plasma, the use of its manufacturing facilities, and access to its R&D resources. IBT will offer specialized training and education to the company’s research staff. The institute will also work to obtain additional funding from national and provincial funding bodies.
“China's plasma-based industry is underpenetrated, partially due to the scarcity of investment in the research and development of new products as compared to similar investment in more developed countries,” according to Chao Ming Zhao, CEO of China Biologic Products. “We are pleased to enter into the research and development agreement with IBT, which we believe will enable us to leverage IBT's advanced scientific resources to accelerate our development of new products and improve the efficiency of our operations.”
Based in Chengdu, IBT is a division of the Chinese Academy of Medical Sciences and Peking Union Medical College. It specializes in plasma-based research including safety of blood transfusions, blood immunology, disposable transfusion materials, blood biochemistry and molecular biology.